A single-site, three-arm, pharmacokinetic Phase I trial of JHL1149 in healthy volunteers

Trial Profile

A single-site, three-arm, pharmacokinetic Phase I trial of JHL1149 in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Cancer
  • Focus Pharmacokinetics
  • Sponsors JHL Biotech
  • Most Recent Events

    • 16 Apr 2018 According to a JHL Biotech media release, the data from this and other trials will support the global registration and commercialization of JHL1149.
    • 01 Mar 2018 According to a JHL Biotech media release, status changed from planning to recruiting.
    • 26 Feb 2018 According to a JHL Biotech media release, Bulgarian Drug Agency has approved Clinical Trial Application (CTA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top